Gabapentin Capsule
Product Images NDC 71335-2748

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2748). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Gabapentin Fig1)

A pharmacokinetic clearance formula labeled CLcr, used to calculate creatinine clearance. The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

A line graph depicting mean pain scores over an 8-week period comparing Gabapentin 3600 mg/day to placebo. The x-axis shows weeks from baseline to week 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score, with Gabapentin showing a decreasing trend while placebo remains relatively stable.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

A line graph depicting the mean pain score over a 7-week period comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline through week 7, while the y-axis measures mean pain score from 0 to 10. The graph shows pain score trends during a 3-week dose titration period followed by a 4-week fixed dose period for Gabapentin doses compared to placebo.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) in two studies. Study 1 shows 12% responders for placebo and 29% for GBP 3600 mg. Study 2 shows 14% responders for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values below 0.01 and 0.001.*

FDA Label Image

Fig-5 (Gabapentin Fig5)

A scatter plot chart showing percentage difference on the vertical axis and daily dose in mg on the horizontal axis. The chart compares data points from three studies labeled 'STUDY a', 'STUDY b', and 'STUDY c', with markers differentiated by black, gray, and white squares, respectively. Data points are plotted at daily doses of 600, 900, 1200, and 1800 mg.*

FDA Label Image

Chemical Structure (Gabapentin Str)

Chemical structure diagram of gabapentin, showing a cyclohexane ring with attached amino and carboxymethyl groups representing the molecule's key functional components.*

FDA Label Image

Label (Lbl713352748)

Label for Gabapentin Capsules USP 300 mg, containing 90 capsules. The label includes storage instructions, warnings, and QR codes for package insert information. It is repackaged by Bryant Ranch Prepack, Inc. in Burbank, CA, and manufactured by Aurobindo Pharma Limited. The NDC is 71335-2748-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.